Table 1 Characteristics of 269 apatinib-treated gastric cancer patients from two clinical trials included in the present study
Without adverse eventsa No. (%) | With adverse events No. (%) | P valueb | |
|---|---|---|---|
Overall | 119 (44.24) | 150 (55.76) | |
Trial | |||
Phase II | 45 (37.82) | 48 (32.00) | 0.319 |
Phase III | 74 (62.18) | 102 (68.00) | |
Age (years) | |||
< 30 | 2 (1.68) | 1 (0.67) | 0.319 |
30–39 | 10 (8.40) | 8 (5.33) | |
40–49 | 23 (19.33) | 26 (17.33) | |
50–59 | 53 (44.54) | 60 (40.00) | |
60–69 | 29 (24.37) | 54 (36.00) | |
≥ 70 | 2 (1.68) | 1 (0.67) | |
Sex | |||
Female | 27 (22.69) | 37 (24.67) | 0.705 |
Male | 92 (77.31) | 113 (75.33) | |
ECOG PS | |||
0 | 21 (17.65) | 32 (21.33) | 0.450 |
1 | 98 (82.35) | 118 (78.67) | |
Stage at diagnosis | |||
II | 2 (1.68) | 1 (0.67) | 0.755 |
III | 7 (5.88) | 6 (4.00) | |
IV | 109 (91.60) | 141 (94.00) | |
Pathological grading | |||
Gx | 12 (10.53) | 21 (15.11) | 0.280 |
G1 | 6 (5.26) | 4 (2.88) | |
G2 | 46 (40.35) | 44 (31.65) | |
G3 | 50 (43.86) | 70 (50.36) | |
No. of metastatic sites | |||
≤ 2 | 79 (66.39) | 104 (69.80) | 0.551 |
> 2 | 40 (33.61) | 45 (30.20) | |
Prior surgery of primary tumor | |||
Yes | 86 (72.27) | 108 (72.00) | 0.961 |
No | 33 (27.73) | 42 (28.00) | |
Prior radiotherapy | |||
Yes | 19 (15.97) | 21 (14.00) | 0.653 |
No | 100 (84.03) | 129 (86.00) | |
Neoadjuvant chemotherapy | |||
Yes | 32 (26.89) | 45 (30.00) | 0.575 |
No | 81 (73.11) | 105 (70.00) | |
Months since diagnosisc | 15.7 (10.1–29.9) | 18.3 (11.8–31.4) | 0.1876 |
Comorbidity | |||
Yes | 29 (24.37) | 44 (29.33) | 0.363 |
No | 90 (75.63) | 106 (70.67) | |
Days since last chemotherapyc | 44 (34–91) | 46 (32–91) | 0.7310 |
Tumor size | |||
≥ 5 cm | 50 (42.02) | 56 (37.33) | 0.435 |
< 5 cm | 69 (57.98) | 94 (62.67) | |